<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm: Cefprozil</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Cefprozil category.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Cefprozil&kid=31902&t=Cefprozil&f=drugs]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 06:36:48 +0100</lastBuildDate>
        <item>
            <title>Efficient biocatalyst for large-scale synthesis of cephalosporins, obtained by combining immobilization and site-directed mutagenesis of penicillin acylase.</title>
            <link>http://www.medworm.com/index.php?rid=5577589&amp;cid=c_31902_77_f&amp;fid=37327&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22228258%26dopt%3DAbstract</link>
            <description>We describe the rational design of a new efficient biocatalyst and the development of a sustainable green process for the synthesis of cephalosporins bearing a NH(2) group on the acyl side chain. The new biocatalyst was developed starting from the WT penicillin acylase (PA) from Escherichia coli by combining enzyme mutagenesis, in position α146 and β24 (βF24A/αF146Y), and immobilization on an appropriate modified industrial support, glyoxyl Eupergit C250L. The obtained derivative was used in the kinetically controlled synthesis of cephalexin, cefprozil and cefaclor and compared to the WT-PA and an already described mutant, PA-βF24A, with improved properties. The new biocatalyst posses a very high ratio between the rates of the synthesis and two undesired hydrolyses (acylating ester an...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Find the best &lt;a href=&quot;http://www.januarysales.org/&quot; target=&quot;_blank&quot;&gt;January Sales&lt;/a&gt; in the UK.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Applied Microbiology and Biotechnology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5577589</comments>
            <pubDate>Sun, 08 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5577589</guid>        </item>
        <item>
            <title>CEFPROZIL (Cefprozil) Tablet [H. J. Harkins Company, Inc.]</title>
            <link>http://www.medworm.com/index.php?rid=5408928&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D55920</link>
            <description>Updated Date: Nov 16, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5408928</comments>
            <pubDate>Wed, 16 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5408928</guid>        </item>
        <item>
            <title>CEFPROZIL (Cefprozil) Tablet [LUPIN PHARMACEUTICALS INC]</title>
            <link>http://www.medworm.com/index.php?rid=4970786&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D46561</link>
            <description>Updated Date: Jun 24, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970786</comments>
            <pubDate>Fri, 24 Jun 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970786</guid>        </item>
        <item>
            <title>Ionization constants and solubility of compounds involved in enzymatic synthesis of aminopenicillins and aminocephalosporins.</title>
            <link>http://www.medworm.com/index.php?rid=5008870&amp;cid=c_31902_169_f&amp;fid=37612&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21698348%26dopt%3DAbstract</link>
            <description>Authors: Kurochkina VB, Sklyarenko AV, Satarova JE, Yarotsky SV
    The article deals with experimental determination of ionization constants and solubility for the compounds (target products, initial β-lactams, acylating agents and by-products) involved in enzymatic synthesis of some therapeutically used aminopenicillins and aminocephalosporins, namely ampicillin, amoxicillin, cephalexin, cephadroxil, cephaloglycin, cefaclor, cefprozil, cefatrizine. Methodology of investigations and the evaluation of experimental data for the determination of ionization constants and solubility of the different type electrolytes are presented. Applications of the methods based on acid-base potentiometric titration and on determination of solubility-pH dependence of assayed substances are discussed. The o...</description>
            <author>Bioprocess and Biosystems Engineering</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5008870</comments>
            <pubDate>Wed, 22 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5008870</guid>        </item>
        <item>
            <title>CEFPROZIL (Cefprozil) Powder, For Suspension [LUPIN PHARMACEUTICALS INC]</title>
            <link>http://www.medworm.com/index.php?rid=4763846&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D42326</link>
            <description>Updated Date: Apr 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4763846</comments>
            <pubDate>Thu, 28 Apr 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">4763846</guid>        </item>
        <item>
            <title>Reversal of refractory sulfasalazine-related renal failure after treatment with corticosteroids.</title>
            <link>http://www.medworm.com/index.php?rid=4205289&amp;cid=c_31902_13_f&amp;fid=35408&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21095485%26dopt%3DAbstract</link>
            <description>Conclusions: Although this isolated case of sulfasalazine- related interstitial nephritis cannot lead to definite conclusions, treatment with corticosteroids was effective in this patient and should be considered irrespective of the time of exposure to sulfasalazine. However, randomized controlled trials are needed to provide evidence regarding the efficacy and tolerability profile of corticosteroids.
    PMID: 21095485 [PubMed - in process] (Source: Clinical Therapeutics)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Please support the &lt;a href=&quot;http://www.doctorsinchains.org/&quot; target=&quot;_blank&quot;&gt;Doctors In Chains&lt;/a&gt; campaign for the &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;medics&lt;/a&gt; tortured and sentenced for up to 15 years in &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;Bahrain&lt;/a&gt;. &lt;a href=&quot;https://twitter.com/#!/search/%23FreeDoctors&quot;&gt;#FreeDoctors&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;</description>
            <author>Clinical Therapeutics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4205289</comments>
            <pubDate>Fri, 01 Oct 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4205289</guid>        </item>
        <item>
            <title>Self-medication with antibiotics in rural population in Greece: a cross-sectional multicenter study</title>
            <link>http://www.medworm.com/index.php?rid=3838820&amp;cid=c_31902_35_f&amp;fid=28830&amp;url=http%3A%2F%2Fwww.biomedcentral.com%2F1471-2296%2F11%2F58</link>
            <description>Conclusion:
In Greece, despite the open and rapid access to primary care services, it appears that a high proportion of rural adult population use antibiotics without medical prescription preferably for fever and common cold. (Source: BMC Family Practice)</description>
            <author>BMC Family Practice</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3838820</comments>
            <pubDate>Sat, 07 Aug 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3838820</guid>        </item>
        <item>
            <title>Aurobindo gets approval from Canada for antibiotic drug</title>
            <link>http://www.medworm.com/index.php?rid=3474220&amp;cid=c_31902_34_f&amp;fid=38573&amp;url=http%3A%2F%2Feconomictimes.indiatimes.com%2Fnews%2Fnews-by-industry%2Fhealthcare%2Fbiotech%2Fpharmaceuticals%2FAurobindo-gets-approval-from-Canada-for-antibiotic-drug%2Farticleshow%2F5819782.cms</link>
            <description>Pharma firm Aurobindo Pharma on Friday said it has received approval from Health Canada for introducing its Cefprozil tablets and Cefprozil powder for oral suspension as an antibiotic. (Source: The Economic Times Healthcare and Biotech News)</description>
            <author>The Economic Times Healthcare and Biotech News</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3474220</comments>
            <pubDate>Fri, 16 Apr 2010 08:47:37 +0100</pubDate>
            <guid isPermaLink="false">3474220</guid>        </item>
        <item>
            <title>Interaction of the heptavalent pneumococcal conjugate vaccine and the use of individual antibiotics among children on nasopharyngeal colonization with erythromycin-resistant Streptococcus pneumoniae</title>
            <link>http://www.medworm.com/index.php?rid=3044235&amp;cid=c_31902_77_f&amp;fid=33419&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F10116wh345564930%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of this study was to assess the complex interaction of the heptavalent pneumococcal conjugate vaccine (PCV7) and
 individual classes of antimicrobial agents on the nasopharyngeal carriage of erythromycin-resistant pneumococci within the
 day-care center population. Between February 2005 and May 2007, nasopharyngeal cultures for Streptococcus pneumoniae were obtained from 1,829 day-care center attendees in Central Greece. Thirty-one percent of the pneumococci were erythromycin-resistant;
 85.2% of these isolates were also penicillin-nonsusceptible. PCV7 immunization was associated with decreased carriage of erythromycin-resistant
 PCV7 serotypes but not with an overall decrease in erythromycin-resistant S. pneumoniae colonization. The largest decline in the c...</description>
            <author>European Journal of Clinical Microbiology &amp; Infectious Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3044235</comments>
            <pubDate>Thu, 26 Nov 2009 07:59:49 +0100</pubDate>
            <guid isPermaLink="false">3044235</guid>        </item>
        <item>
            <title>Cefprozil: First report of acute generalised exanthematous pustulosis with severe organ dysfunction: case report</title>
            <link>http://www.medworm.com/index.php?rid=3016127&amp;cid=c_31902_13_f&amp;fid=33942&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Frea%2F2009%2F00000001%2F00001279%2Fart00034</link>
            <description>(Source: Reactions)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Find the best &lt;a href=&quot;http://www.januarysales.org/&quot; target=&quot;_blank&quot;&gt;January Sales&lt;/a&gt; in the UK.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Reactions</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016127</comments>
            <pubDate>Sun, 22 Nov 2009 14:04:51 +0100</pubDate>
            <guid isPermaLink="false">3016127</guid>        </item>
        <item>
            <title>cefprozil, Cefzil</title>
            <link>http://www.medworm.com/index.php?rid=2873172&amp;cid=c_31902_3_f&amp;fid=33184&amp;url=http%3A%2F%2Fwww.medicinenet.com%2Fguide.asp%3Fs%3Drss%26a%3D717%26k%3DAllergies_General</link>
            <description>Title: cefprozil, CefzilCategory: MedicationsCreated: 12/31/1997Last Editorial Review: 10/8/2009 (Source: MedicineNet Allergies General)</description>
            <author>MedicineNet Allergies General</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2873172</comments>
            <pubDate>Thu, 08 Oct 2009 07:00:00 +0100</pubDate>
            <guid isPermaLink="false">2873172</guid>        </item>
        <item>
            <title>Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics</title>
            <link>http://www.medworm.com/index.php?rid=2176952&amp;cid=c_31902_77_f&amp;fid=32011&amp;url=http%3A%2F%2Fjac.oxfordjournals.org%2Fcgi%2Fcontent%2Fshort%2F63%2F3%2F511%3Frss%3D1</link>
            <description>Conclusions
Despite high rates of &amp;beta;-lactamase production among non-typeable H. influenzae and M. catarrhalis, multiple oral treatment options exist for non-typeable H. influenzae and M. catarrhalis. Multidrug-resistant serotype 19A S. pneumoniae (~20%) limits treatment options for ambulatory S. pneumoniae respiratory disease. (Source: Journal of Antimicrobial Chemotherapy)</description>
            <author>Journal of Antimicrobial Chemotherapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2176952</comments>
            <pubDate>Wed, 11 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2176952</guid>        </item>
        <item>
            <title>Probability of Achieving Requisite Pharmacodynamic Exposure for Oral beta-Lactam Regimens against Haemophilus influenzae in Children.</title>
            <link>http://www.medworm.com/index.php?rid=1955898&amp;cid=c_31902_33_f&amp;fid=36854&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18998749%26dopt%3DAbstract</link>
            <description>CONCLUSION: Against H. influenzae, the antibacterials most likely to achieve optimal in vivo exposures in children are cefpodoxime, ceftibuten, and amoxicillin/clavulanic acid.
    PMID: 18998749 [PubMed - in process] (Source: Paediatric Drugs)</description>
            <author>Paediatric Drugs</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1955898</comments>
            <pubDate>Thu, 13 Nov 2008 16:53:44 +0100</pubDate>
            <guid isPermaLink="false">1955898</guid>        </item>
        <item>
            <title>Pharmacodynamic Target Attainment of Oral beta-Lactams for the Empiric Treatment of Acute Otitis Media in Children.</title>
            <link>http://www.medworm.com/index.php?rid=1747586&amp;cid=c_31902_33_f&amp;fid=36854&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18754699%26dopt%3DAbstract</link>
            <description>CONCLUSIONS: Based on the recent epidemiologic and resistance profiles of S. pneumoniae and H. influenzae, amoxicillin/clavulanic acid (45 mg/kg every 12 hours) and cefpodoxime (5 mg/kg every 12 hours) provide the greatest likelihood of achieving optimal pharmacodynamic exposures empirically in children with AOM.
    PMID: 18754699 [PubMed - in process] (Source: Paediatric Drugs)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Find the best &lt;a href=&quot;http://www.januarysales.org/&quot; target=&quot;_blank&quot;&gt;January Sales&lt;/a&gt; in the UK.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Paediatric Drugs</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1747586</comments>
            <pubDate>Sun, 31 Aug 2008 13:27:11 +0100</pubDate>
            <guid isPermaLink="false">1747586</guid>        </item>
        <item>
            <title>Cefprozil(CEFPROZIL) Tablet, Film Coated [ORCHID HEALTHCARE (A DIVISION OF ORCHID CHEMICALS AND PHARMACEUTICALS LTD.)]</title>
            <link>http://www.medworm.com/index.php?rid=1464101&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D7402</link>
            <description>Updated Date: May 22, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1464101</comments>
            <pubDate>Thu, 22 May 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1464101</guid>        </item>
        <item>
            <title>Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.</title>
            <link>http://www.medworm.com/index.php?rid=1319466&amp;cid=c_31902_77_f&amp;fid=35514&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18353594%26dopt%3DAbstract</link>
            <description>Authors: Biedenbach DJ, Jones RN, Fritsche TR
    Among orally administered cephalosporins, aminopenicillins (+/-clavulanate), and macrolides, cefditoren was the most potent agent against Haemophilus influenzae (MIC(50/90), &amp;lt;/=0.008/0.03 mug/mL; 316 isolates including 100 beta-lactamase-positive and 10 beta-lactamase-negative ampicillin-resistant [BLNAR]) and was 32-, 64-, and 512-fold more potent than cefdinir, cefuroxime, and cefprozil, respectively. Cefditoren (MIC(50), 0.03 mug/mL) was also &amp;gt;/=32-fold more active against BLNAR phenotypes, although newer macrolides provided complete coverage against these strains. All Moraxella catarrhalis isolates were inhibited by cefditoren (0.5 mug/mL), including beta-lactamase producers (MIC(50), 0.12 vs &amp;lt;/=0.008 mug/mL). Cefditoren retain...</description>
            <author>Diagnostic Microbiology and Infectious Disease</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1319466</comments>
            <pubDate>Tue, 18 Mar 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1319466</guid>        </item>
        <item>
            <title>Cefzil(CEFPROZIL) Tablet, Film Coated Cefzil(CEFPROZIL) Powder, For Suspension [Bristol-Myers Squibb]</title>
            <link>http://www.medworm.com/index.php?rid=1280930&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6646</link>
            <description>Updated Date: Mar 5, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1280930</comments>
            <pubDate>Wed, 05 Mar 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1280930</guid>        </item>
        <item>
            <title>Comparison of the effect of benzathine penicillin G, clarithromycin, cefprozil and amoxicillin/clavulanate on the bacteriological response and throat flora in group A beta hemolytic streptococcal tonsillopharyngitis.</title>
            <link>http://www.medworm.com/index.php?rid=1671952&amp;cid=c_31902_33_f&amp;fid=36152&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18664074%26dopt%3DAbstract</link>
            <description>Authors: Yildirim I, Ceyhan M, G&amp;#xFC;r D, Kaymako&amp;#x11F;lu I
    Bacteriological failure with penicillin that has been used widely for years in group A beta hemolytic streptococcal (GABHS) tonsillopharyngitis is being reported as high as 30%. Because of this unresponsiveness, many different agents are being used as alternative options. We evaluated the effect of clarithromycin, amoxicillin/clavulanate (CAM), cefprozil and benzathine penicillin G (Pen G) on the bacteriological cure, beta-lactamase production, pharyngeal microflora and alpha hemolytic streptococci (AHS) when used in the treatment of pediatric GABHS tonsillopharyngitis. Intramuscular Pen G and oral clarithromycin, CAM and cefprozil were administered to 70 patients who were between 2-16 years of age. Three throat swabs were o...</description>
            <author>The Turkish Journal of Pediatrics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1671952</comments>
            <pubDate>Sat, 01 Mar 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1671952</guid>        </item>
        <item>
            <title>Cefprozil(Cefprozil) Tablet, Film Coated [TEVA PHARMACEUTICALS USA]</title>
            <link>http://www.medworm.com/index.php?rid=1261763&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6626</link>
            <description>Updated Date: Feb 27, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Please support the &lt;a href=&quot;http://www.doctorsinchains.org/&quot; target=&quot;_blank&quot;&gt;Doctors In Chains&lt;/a&gt; campaign for the &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;medics&lt;/a&gt; tortured and sentenced for up to 15 years in &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;Bahrain&lt;/a&gt;. &lt;a href=&quot;https://twitter.com/#!/search/%23FreeDoctors&quot;&gt;#FreeDoctors&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1261763</comments>
            <pubDate>Wed, 27 Feb 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1261763</guid>        </item>
        <item>
            <title>Cefprozil(CEFPROZIL) Powder, For Suspension [ORCHID HEALTHCARE (A DIVISION OF ORCHID CHEMICALS AND PHARMACEUTICALS LTD.)]</title>
            <link>http://www.medworm.com/index.php?rid=1261779&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6642</link>
            <description>Updated Date: Feb 27, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1261779</comments>
            <pubDate>Wed, 27 Feb 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1261779</guid>        </item>
        <item>
            <title>Cefprozil(CEFPROZIL) Tablet, Film Coated [ORCHID HEALTHCARE (A DIVISION OF ORCHID CHEMICALS AND PHARMACEUTICALS LTD.)]</title>
            <link>http://www.medworm.com/index.php?rid=1250395&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6611</link>
            <description>Updated Date: Feb 22, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1250395</comments>
            <pubDate>Fri, 22 Feb 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1250395</guid>        </item>
        <item>
            <title>Cefprozil(Cefprozil) Tablet, Film Coated [Lupin Pharmaceuticals, Inc.]</title>
            <link>http://www.medworm.com/index.php?rid=1177820&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6133</link>
            <description>Updated Date: Jan 25, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1177820</comments>
            <pubDate>Fri, 25 Jan 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1177820</guid>        </item>
        <item>
            <title>Cefprozil(CEFPROZIL) Powder, For Suspension [Lupin Pharmaceuticals, Inc.]</title>
            <link>http://www.medworm.com/index.php?rid=1177833&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6146</link>
            <description>Updated Date: Jan 25, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1177833</comments>
            <pubDate>Fri, 25 Jan 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1177833</guid>        </item>
        <item>
            <title>Cefprozil(Cefprozil) Powder, For Suspension [Aurobindo Pharma Limited]</title>
            <link>http://www.medworm.com/index.php?rid=1177855&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D6168</link>
            <description>Updated Date: Jan 25, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Find the best &lt;a href=&quot;http://www.januarysales.org/&quot; target=&quot;_blank&quot;&gt;January Sales&lt;/a&gt; in the UK.&lt;/p&gt;&lt;/div&gt;</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1177855</comments>
            <pubDate>Fri, 25 Jan 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1177855</guid>        </item>
        <item>
            <title>Redefining the management of pediatric tonsillopharyngitis with Cefprozil</title>
            <link>http://www.medworm.com/index.php?rid=1173310&amp;cid=c_31902_33_f&amp;fid=35971&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp113875r05r708w5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Tonsillopharyngitis is very common in children, with Group A Streptococci being the most common bacterial etiology. Effective
 antibacterial treatment is imperative due to risk of rheumatic fever. Cephalosporins have been used successfully for the treatment
 of Group A beta-hemolytic Streptococcal (GABHS) tonsillopharyngitis. Cefprozil is a novel broad-spectrum oral cephalosporin.
 Cefprozil is rapidly absorbed from the gastrointestinal tract with high bioavailability. The excellent penetration of cefprozil
 into tonsillar and adenoidal tissue corresponds well with the clinical outcome. The drug provides excellent coverage against
 both gram-negative and-positive bacteria that may cause pharyngitis/tonsillitis. The beta-lactamase stability of cefprozil
 appears to excee...</description>
            <author>Indian Journal of Pediatrics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1173310</comments>
            <pubDate>Mon, 21 Jan 2008 16:13:25 +0100</pubDate>
            <guid isPermaLink="false">1173310</guid>        </item>
        <item>
            <title>Cefprozil(Cefprozil) Tablet, Film Coated [Lek Pharmaceuticals Inc.]</title>
            <link>http://www.medworm.com/index.php?rid=941951&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D5528</link>
            <description>Updated Date: Oct 10, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=941951</comments>
            <pubDate>Wed, 10 Oct 2007 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">941951</guid>        </item>
        <item>
            <title>A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005</title>
            <link>http://www.medworm.com/index.php?rid=797609&amp;cid=c_31902_77_f&amp;fid=32011&amp;url=http%3A%2F%2Fjac.oxfordjournals.org%2Fcgi%2Fcontent%2Fshort%2F60%2F3%2F587%3Frss%3D1</link>
            <description>Conclusions
Prevalence of penicillin and macrolide&amp;ndash;azalide resistance among S. pneumoniae appears to be on the increase in Turkey while overall &amp;szlig;-lactamase production in H. influenzae remains relatively low. To adequately monitor the spread of drug-resistant phenotypes among these two important CARTI pathogens, ongoing collection of resistance surveillance data is required&amp;mdash;where possible locally as resistance patterns can vary substantially between cities and institutions. (Source: Journal of Antimicrobial Chemotherapy)</description>
            <author>Journal of Antimicrobial Chemotherapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=797609</comments>
            <pubDate>Tue, 14 Aug 2007 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">797609</guid>        </item>
        <item>
            <title>Cefprozil(Cefprozil) Powder, For Suspension [Aurobindo Pharma Limited]</title>
            <link>http://www.medworm.com/index.php?rid=718902&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D4556</link>
            <description>Updated Date: Jul 6, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=718902</comments>
            <pubDate>Fri, 06 Jul 2007 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">718902</guid>        </item>
        <item>
            <title>Cefzil(Cefprozil) Tablet, Film Coated Cefzil(Cefprozil) Powder, For Suspension [Bristol-Myers Squibb]</title>
            <link>http://www.medworm.com/index.php?rid=704629&amp;cid=c_31902_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fid%3D4520</link>
            <description>Updated Date: Jun 29, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Please support the &lt;a href=&quot;http://www.doctorsinchains.org/&quot; target=&quot;_blank&quot;&gt;Doctors In Chains&lt;/a&gt; campaign for the &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;medics&lt;/a&gt; tortured and sentenced for up to 15 years in &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;Bahrain&lt;/a&gt;. &lt;a href=&quot;https://twitter.com/#!/search/%23FreeDoctors&quot;&gt;#FreeDoctors&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=704629</comments>
            <pubDate>Fri, 29 Jun 2007 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">704629</guid>        </item>
        <item>
            <title>Oral cefprozil has good penetration into the middle ear fluid (MEF) of paediatric patients with acute otitis media</title>
            <link>http://www.medworm.com/index.php?rid=573621&amp;cid=c_31902_13_f&amp;fid=33934&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Finp%2F2007%2F00000001%2F00001584%2Fart00064</link>
            <description>(Source: Inpharma)</description>
            <author>Inpharma</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=573621</comments>
            <pubDate>Fri, 27 Apr 2007 18:40:04 +0100</pubDate>
            <guid isPermaLink="false">573621</guid>        </item>
        <item>
            <title>Oral cefprozil has good penetration into the middle ear fluid (MEF) of paediatric patients with acute otitis media.</title>
            <link>http://www.medworm.com/index.php?rid=558681&amp;cid=c_31902_13_f&amp;fid=34370&amp;url=http%3A%2F%2Finpharma.adisonline.com%2Fpt%2Fre%2Finp%2Fabstract.00128413-200715840-00065.htm</link>
            <description>Page: 23 (Source: Inpharma Weekly)</description>
            <author>Inpharma Weekly</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=558681</comments>
            <pubDate>Sat, 21 Apr 2007 18:22:03 +0100</pubDate>
            <guid isPermaLink="false">558681</guid>        </item>
        <item>
            <title>Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid: In Children Undergoing Treatment for Acute Otitis Media</title>
            <link>http://www.medworm.com/index.php?rid=528497&amp;cid=c_31902_33_f&amp;fid=33938&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Fped%2F2007%2F00000009%2F00000002%2Fart00005</link>
            <description>(Source: Pediatric Drugs)</description>
            <author>Pediatric Drugs</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=528497</comments>
            <pubDate>Sun, 08 Apr 2007 01:10:05 +0100</pubDate>
            <guid isPermaLink="false">528497</guid>        </item>
        <item>
            <title>Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid: In Children Undergoing Treatment for Acute Otitis Media.</title>
            <link>http://www.medworm.com/index.php?rid=524722&amp;cid=c_31902_33_f&amp;fid=34366&amp;url=http%3A%2F%2Fpediatrics.adisonline.com%2Fpt%2Fre%2Fpdd%2Fabstract.00148581-200709020-00005.htm</link>
            <description>Page: 119Authors: Nicolau, David P 1; Sutherland, Christina A 1; Arguedas, Adriano 2; Dagan, Ron 3; Pichichero, Micheal E 4 (Source: Pediatric Drugs)</description>
            <author>Pediatric Drugs</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=524722</comments>
            <pubDate>Fri, 06 Apr 2007 11:54:03 +0100</pubDate>
            <guid isPermaLink="false">524722</guid>        </item>
        <item>
            <title>Cefprozil: Hepatitis: case report</title>
            <link>http://www.medworm.com/index.php?rid=454995&amp;cid=c_31902_13_f&amp;fid=33942&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Frea%2F2007%2F00000001%2F00001141%2Fart00034</link>
            <description>(Source: Reactions)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Find the best &lt;a href=&quot;http://www.januarysales.org/&quot; target=&quot;_blank&quot;&gt;January Sales&lt;/a&gt; in the UK.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Reactions</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=454995</comments>
            <pubDate>Wed, 07 Mar 2007 19:55:13 +0100</pubDate>
            <guid isPermaLink="false">454995</guid>        </item>
        <item>
            <title>Cefprozil: Hepatitis: case report.</title>
            <link>http://www.medworm.com/index.php?rid=441596&amp;cid=c_31902_13_f&amp;fid=34372&amp;url=http%3A%2F%2Freactions.adisonline.com%2Fpt%2Fre%2Frea%2Fabstract.00128415-200711410-00036.htm</link>
            <description>(Source: Reactions Weekly)</description>
            <author>Reactions Weekly</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=441596</comments>
            <pubDate>Sat, 03 Mar 2007 08:20:09 +0100</pubDate>
            <guid isPermaLink="false">441596</guid>        </item>
        <item>
            <title>Cefalexin/cefprozil: Fatal hypersensitivity myocarditis (first report with cefprozil) in children: 2 case reports</title>
            <link>http://www.medworm.com/index.php?rid=388157&amp;cid=c_31902_13_f&amp;fid=33942&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Frea%2F2007%2F00000001%2F00001136%2Fart00024</link>
            <description>(Source: Reactions)</description>
            <author>Reactions</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=388157</comments>
            <pubDate>Wed, 31 Jan 2007 10:25:03 +0100</pubDate>
            <guid isPermaLink="false">388157</guid>        </item>
        <item>
            <title>Cefalexin/cefprozil: Fatal hypersensitivity myocarditis (first report with cefprozil) in children: 2 case reports.</title>
            <link>http://www.medworm.com/index.php?rid=382824&amp;cid=c_31902_13_f&amp;fid=34372&amp;url=http%3A%2F%2Freactions.adisonline.com%2Fpt%2Fre%2Frea%2Fabstract.00128415-200711360-00021.htm</link>
            <description>(Source: Reactions Weekly)</description>
            <author>Reactions Weekly</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=382824</comments>
            <pubDate>Sat, 27 Jan 2007 05:39:02 +0100</pubDate>
            <guid isPermaLink="false">382824</guid>        </item>
        <item>
            <title>Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.</title>
            <link>http://www.medworm.com/index.php?rid=1227488&amp;cid=c_31902_33_f&amp;fid=36854&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17407367%26dopt%3DAbstract</link>
            <description>CONCLUSIONS: The plasma profile of cefprozil in the current analysis is consistent with previously reported values in children receiving the 15 mg/kg twice daily dose. MEF penetration and the duration of drug exposure at the site of infection support the clinical utility of this agent for organisms with minimum inhibitory concentrations (MIC) of &amp;lt; or =1 microg/mL. However, these results also predict higher clinical failure when using this dose of cefprozil against penicillin-non-susceptible Streptococcus pneumoniae or Haemophilus influenzae because of typically higher MIC values for these organisms.
    PMID: 17407367 [PubMed - indexed for MEDLINE] (Source: Paediatric Drugs)</description>
            <author>Paediatric Drugs</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1227488</comments>
            <pubDate>Mon, 01 Jan 2007 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1227488</guid>        </item>
        <item>
            <title>Ranbaxy Is Granted Final Approval To Manufacture And Market Cefprozil Anti- Infective Tablets</title>
            <link>http://www.medworm.com/index.php?rid=320667&amp;cid=c_31902_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Fmedicalnews.php%3Fnewsid%3D59096%26nfid%3Drssfeeds</link>
            <description>Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Cefprozil Tablets USP, 250 mg and 500 mg. The Office of Generic Drugs, U.S. [click link for full article] (Source: Health News from Medical News Today)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Please support the &lt;a href=&quot;http://www.doctorsinchains.org/&quot; target=&quot;_blank&quot;&gt;Doctors In Chains&lt;/a&gt; campaign for the &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;medics&lt;/a&gt; tortured and sentenced for up to 15 years in &lt;a href=&quot;http://www.doctorsinchains.org/&quot;&gt;Bahrain&lt;/a&gt;. &lt;a href=&quot;https://twitter.com/#!/search/%23FreeDoctors&quot;&gt;#FreeDoctors&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=320667</comments>
            <pubDate>Fri, 15 Dec 2006 08:00:00 +0100</pubDate>
            <guid isPermaLink="false">320667</guid>        </item>
        <item>
            <title>Ranbaxy Receives Approval To Market Cefprozil Suspension</title>
            <link>http://www.medworm.com/index.php?rid=85779&amp;cid=c_31902_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Fmedicalnews.php%3Fnewsid%3D46361%26nfid%3Drssfeeds</link>
            <description>Ranbaxy Pharmaceuticals Inc.(RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received approval from the U.S. Food and DrugAdministration to manufacture and market Cefprozil for Oral Suspension USP,125 mg/5mL and 250 mg/5mL. The Office of Generic Drugs, U.S. [click link for full article] (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=85779</comments>
            <pubDate>Mon, 03 Jul 2006 07:00:00 +0100</pubDate>
            <guid isPermaLink="false">85779</guid>        </item>
        <item>
            <title>Ranbaxy Receives Approval to Market Cefprozil Suspension</title>
            <link>http://www.medworm.com/index.php?rid=85153&amp;cid=c_31902_34_f&amp;fid=22558&amp;url=http%3A%2F%2Fwww.drugnewswire.com%2F2964%2F</link>
            <description>PRINCETON, N.J., June 30 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Cefprozil for Oral Suspension USP, 125 mg/5mL and 250 mg/5mL. The Office of... (Source: Drug Newswire)</description>
            <author>Drug Newswire</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=85153</comments>
            <pubDate>Sat, 01 Jul 2006 06:00:00 +0100</pubDate>
            <guid isPermaLink="false">85153</guid>        </item>
        <item>
            <title>Cefprozil (Cefzil) discontinued</title>
            <link>http://www.medworm.com/index.php?rid=70531&amp;cid=c_31902_13_f&amp;fid=32547&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2FRecord%2520Viewing%2FviewRecord.aspx%3Fid%3D566812</link>
            <description>For commercial reasons, cefprozil (Cefzil) has been discontinued by Bristol-Myers-Squibb. For further information, please call medical information on 0800 731 1736. (Source: NeLM Headline News)</description>
            <author>NeLM Headline News</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=70531</comments>
            <pubDate>Wed, 21 Jun 2006 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">70531</guid>        </item>
        <item>
            <title>Lupin Receives US FDA Approval for Cefprozil Tablets</title>
            <link>http://www.medworm.com/index.php?rid=7830&amp;cid=c_31902_34_f&amp;fid=22558&amp;url=http%3A%2F%2Fwww.drugnewswire.com%2F1410%2F</link>
            <description>MUMBAI, India - Lupin Ltd. today announced that it has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Cefprozil Tablets USP, 250 mg and 500 mg. Cefprozil is the generic equivalent of Bristol-Myers Squibb's Cefzil(R). The tablet market in the US is USD 117 million as... (Source: Drug Newswire)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Find the best &lt;a href=&quot;http://www.januarysales.org/&quot; target=&quot;_blank&quot;&gt;January Sales&lt;/a&gt; in the UK.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Drug Newswire</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7830</comments>
            <pubDate>Sat, 20 May 2006 06:00:00 +0100</pubDate>
            <guid isPermaLink="false">7830</guid>        </item>
    </channel>
</rss>

